ReviewLe infezioni in medicina2022
Clinical impact of COVID-19 on tuberculosis.
Review in Le infezioni in medicina, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Epidemiological profile of patients undergoing microbiological testing for tuberculosis at a tertiary hospital in the Jazan region, Saudi Arabia: A retrospective study.New microbes and new infections · 2026Article
- Computational approaches: atom-based 3D-QSAR, molecular docking, ADME-Tox, MD simulation and DFT to find novel multi-targeted anti-tubercular agents.BMC chemistry · 2025Article
- Impact of the COVID-19 pandemic on tuberculosis services in a rural area of Senegal.Le infezioni in medicina · 2025Article
- Stigma and Associated Sex Disparities Among Patients with Tuberculosis in Uganda: A Cross-Sectional Study.Research square · 2024Article
- The Predicted Potential Impact of COVID-19 Pandemic on Tuberculosis Epidemic in Tamil Nadu, South India.Tropical medicine and infectious disease · 2024Article
- Tuberculosis morbidity and mortality during the COVID-19 pandemic: a life-threatening complex challenge.Frontiers in cellular and infection microbiology · 2024Article
- Antibodies as clinical tools for tuberculosis.Frontiers in immunology · 2023Review
- Immune interaction between SARS-CoV-2 andFrontiers in immunology · 2023Review
- Disseminated tuberculosis and diagnosis delay during the COVID-19 era in a Western European country: a case series analysis.Frontiers in public health · 2023Article
- COVID-19 and tuberculosis coinfection: outcomes depend on severity of COVID-19 and comorbid conditions.Le infezioni in medicina · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During COVID-19 pandemic, a lot of diseases suffered from a limited access to health care services, owing to the use of resources, both technical and financial, mainly directed towards such a dramatic outbreak. Among these, tuberculosis (TB) has been one of the most penalized, with a huge delay both in diagnosis and in start of treatment, with a consequential dramatic increase in morbidity and mortality. COVID-19 and tuberculosis share similar common pathogenetic pathways, and both diseases affect primarily the lungs. About the impact of TB on COVID-19 severity and mortality, data are unclear and literature reports are often conflicting. Certainly, considering the management of coinfected patients, there are pharmacokinetic interactions between several drugs used for the therapy of SARS-CoV-2 infection and the treatment of TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.